Financials in USD. Standardized financial statements.
A compact view of how COSCIENS Biopharma Inc. turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $13.78M | $7.14M | $14.57M | $13.49M | $11.86M | $9.86M | $8.51M | $10.28M | $10.17M | $7.69M |
| Revenue Growth? | +93.0% | -51.0% | +8.1% | +13.7% | +20.3% | +15.8% | -17.2% | +1.0% | +32.3% | 0.0% |
| Cost of Revenue? | $6.98M | $4.21M | $6.02M | $5.28M | $5.88M | $5.69M | $4.00M | $4.50M | $3.21M | $2.62M |
| Gross Profit? | $6.80M | $2.94M | $8.56M | $8.21M | $5.98M | $4.17M | $4.51M | $5.78M | $6.96M | $5.06M |
| Gross Margin? | +49.3% | +41.1% | +58.7% | +60.9% | +50.4% | +42.3% | +52.9% | +56.3% | +68.4% | +65.9% |
| Operating Expenses? | $33.08M | $7.57M | $4.24M | $5.78M | $4.32M | $4.62M | $4.41M | $3.67M | $2.49M | $2.45M |
| Operating Income? | -$18.28M | -$4.63M | $4.32M | -$10.96M | $1.66M | -$449,108 | $94,034 | $2.11M | $4.46M | $2.62M |
| EBITDA? | -$13.49M | -$2.79M | $6.14M | $4.18M | $3.04M | -$393,102 | $13.51M | -$29,110 | $4.29M | $3.08M |
| Income Before Tax | -$15.22M | -$4.37M | $4.53M | $2.59M | $1.46M | -$869,679 | -$676,363 | -$339,417 | $3.99M | $2.76M |
| Income Tax Expense | $84,000 | -$885,000 | $1.08M | -$52,919 | $0 | -$2,608 | -$444,696 | $422,630 | $1.30M | -$784,125 |
| Net Income? | -$15.31M | -$3.48M | $3.45M | $2.64M | $1.46M | -$867,070 | -$231,666 | -$762,047 | $2.69M | $3.55M |
| EPS? | $-5.93 | $-1.89 | $2.54 | $1.33 | $0.85 | $-0.48 | $-0.13 | $-0.43 | $2.13 | $3.38 |
| Diluted EPS? | $-5.93 | $-1.89 | $1.86 | $1.33 | $0.85 | $-0.48 | $-0.13 | $-0.43 | $2.13 | $3.38 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality